TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, the first generic of Climara Pro. The once-weekly treatment is indicated for moderate to severe menopause-related vasomotor symptoms and prevention of postmenopausal osteoporosis in women with an intact uterus. When the product will be available and its price have not been announced.
The U.S. Food and Drug Administration has approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, the first generic version of Climara Pro, for women with an intact uterus. The once-weekly patch is indicated to treat moderate to severe vasomotor symptoms due to menopause and to prevent postmenopausal osteoporosis.
The FDA’s news release, dated October 20, 2026, said the agency approved the product the day before. The patch contains estradiol and levonorgestrel at strengths listed as 0.045 mg per day and 0.015 mg, respectively, and is therapeutically equivalent to Climara Pro, according to the agency. Climara Pro is a registered trademark of Bayer.
Unlike estrogen-only patches commonly used in menopause treatment, this product combines estrogen and progestogen in one patch. The FDA says it is specifically approved for women with an intact uterus; the progestogen is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. Patients should consult a health professional about whether this treatment is appropriate for them.
The FDA lists contraindications that include undiagnosed abnormal genital bleeding; current or previous breast cancer; estrogen-dependent neoplasia; active or past deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease; liver disease or impairment; and certain thrombophilic disorders. The agency also lists known hypersensitivity to estradiol or levonorgestrel. Common adverse reactions reported at a rate of 5% or more include application-site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome.
A New Generic Menopause Patch
The approval adds a generic option to a category of prescription hormone therapy for people seeking treatment for menopause-related symptoms or prevention of postmenopausal osteoporosis. Generic competition can affect the range of available products and may put pressure on prices, but the FDA release does not state the generic’s price or quantify expected savings.
The weekly application schedule distinguishes the patch from daily oral medicines, while the combined hormones distinguish it from estrogen-only patches. Those characteristics do not establish that it is suitable for every patient. The FDA’s listed contraindications and potential adverse reactions underscore the need for an individual discussion with a prescriber about benefits, risks and alternatives.
As an affiliate, we earn on qualifying purchases.
How the Patch Is Used
Climara Pro is a transdermal hormone therapy: the medicine is delivered through a patch on the skin. The FDA says both the brand-name product and the approved generic are applied once a week and contain estrogen and progestogen together. The approved uses are limited to treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis in women with an intact uterus.
The agency described the approval as consistent with its Public Health Pillar on access to affordable medicines and medical products. It also noted that nine out of 10 prescriptions filled in the United States are for generic drugs, and said more generic availability can support market competition and access. That general point does not establish the price or availability of this particular product.
““Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible.””
— Kyle Diamantas, acting FDA commissioner
estradiol levonorgestrel transdermal patch
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Price and Supply Still Unknown
The FDA said patients should contact the manufacturer for information about when the generic will be available. The release does not provide a launch date, expected supply, retail price or estimated savings compared with Climara Pro. It also does not give details about the approval’s commercial rollout or explain whether the manufacturer expects any supply constraints.
The approval establishes therapeutic equivalence to the brand-name product, as stated by the FDA, but it does not determine whether the treatment is appropriate for a particular person. Individual medical history, contraindications, side effects and treatment goals remain matters for discussion with a health professional.
weekly hormone replacement patch for women
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Watch for Availability Details
Zydus Pharmaceuticals is the manufacturer named in the FDA announcement. The agency directed consumers to contact the company for availability information; no further timing was provided in the release. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is also listed as a resource for approved drug information.
Patients considering the generic should speak with their prescriber or pharmacist about whether it matches their needs and how to use it safely. The FDA announcement does not identify a date for additional updates or provide a price, so those details remain dependent on information from the manufacturer and sellers.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel transdermal system, the first generic version of Climara Pro, according to its announcement.
Who is the patch indicated for?
The FDA lists its uses for women with an intact uterus: treating moderate to severe vasomotor symptoms due to menopause and preventing postmenopausal osteoporosis. A prescriber can advise whether it is suitable for an individual patient.
How often is the patch applied?
The product is applied once a week, according to the FDA. It combines estradiol, an estrogen, with levonorgestrel, a progestogen.
When will the generic be available, and how much will it cost?
The FDA release does not give a launch date or price. It advises consumers to contact the manufacturer for availability information; expected savings have not been announced.
What safety information did the FDA highlight?
The agency lists contraindications including certain cancers, blood clots, liver disease, undiagnosed abnormal genital bleeding and some clotting disorders. Listed common adverse reactions include application-site reactions, vaginal bleeding and breast pain. Patients should review the full prescribing information and discuss their medical history with a health professional.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
